Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 22, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares, specifically relating to the GlaxoSmithKline Employee Trust ("GSK Trust").
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes and Transactions
The following transactions involving the GSK Trust were reported:
- March 16, 2006: The GSK Trust sold 1,449 Ordinary Shares at GBP 15.44 per share on behalf of participants in the GlaxoSmithKline Restricted Share Plan.
- March 16, 2006: The GSK Trust transferred 5,989 Ordinary Shares to participants in the GlaxoSmithKline Restricted Share Plan.
- March 17, 2006: The GSK Trust transferred 47,157 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
The company was advised of these transactions on March 21, 2006.
Management Commentary and Risks
The GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Consequently, three directors—Dr. J-P Garnier, Dr. T Yamada, and Mr. J S Heslop—hold an interest in the shares held by the trust in the same manner as other employees. The filing notes no specific risks, contingencies, or unusual items beyond the routine administration of employee share plans.
Investor Verification Checklist
- Verify the total number of shares transferred to the SmithKline Beecham Employee Share Option Plan 1991 (47,157 shares).
- Confirm the sale price of GBP 15.44 per share for the 1,449 shares sold on March 16, 2006.
- Review the specific interests of Directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J S Heslop in the GSK Trust.
- Note that this filing does not contain financial performance data for the period.